{"protocolSection": {"identificationModule": {"nctId": "NCT02099110", "orgStudyIdInfo": {"id": "8835-005"}, "secondaryIdInfos": [{"id": "MK-8835-005", "type": "OTHER", "domain": "Merck, Sharp & Dohme"}, {"id": "B1521019", "type": "OTHER", "domain": "Pfizer"}, {"id": "2013-003698-82", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)", "officialTitle": "A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-04-22", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-05-26", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-05-26", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-03-25", "studyFirstSubmitQcDate": "2014-03-25", "studyFirstPostDateStruct": {"date": "2014-03-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-08-10", "resultsFirstSubmitQcDate": "2017-10-02", "resultsFirstPostDateStruct": {"date": "2017-11-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-08-14", "lastUpdatePostDateStruct": {"date": "2018-09-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or alone along with metformin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone.", "detailedDescription": "This study will include a 1-week screening period; an up to 12-week metformin titration/dose stabilization period; a 2-week single-blind placebo run-in period; a 52-week (26-week Phase A and 26-week Phase B) double-blind treatment period and a post-treatment telephone contact 14 days after the last dose of study medication."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1233, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ertugliflozin 5 mg + sitagliptin 100 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks", "interventionNames": ["Drug: Matching Placebo to Ertugliflozin 10 mg", "Drug: Ertugliflozin 5 mg", "Drug: Sitagliptin 100 mg", "Drug: Metformin >= 1500 mg/day", "Biological: Insulin Glargine Rescue Medication", "Drug: Glimepiride Rescue Medication"]}, {"label": "Ertugliflozin 15 mg + sitagliptin 100 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks", "interventionNames": ["Drug: Ertugliflozin 5 mg", "Drug: Ertugliflozin 10 mg", "Drug: Sitagliptin 100 mg", "Drug: Metformin >= 1500 mg/day", "Biological: Insulin Glargine Rescue Medication", "Drug: Glimepiride Rescue Medication"]}, {"label": "Ertugliflozin 5 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks", "interventionNames": ["Drug: Matching Placebo to Ertugliflozin 10 mg", "Drug: Matching Placebo to sitagliptin 100 mg", "Drug: Ertugliflozin 5 mg", "Drug: Metformin >= 1500 mg/day", "Biological: Insulin Glargine Rescue Medication", "Drug: Glimepiride Rescue Medication"]}, {"label": "Ertugliflozin 15 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin, oral, once daily for 52 weeks", "interventionNames": ["Drug: Matching Placebo to sitagliptin 100 mg", "Drug: Ertugliflozin 5 mg", "Drug: Ertugliflozin 10 mg", "Drug: Metformin >= 1500 mg/day", "Biological: Insulin Glargine Rescue Medication", "Drug: Glimepiride Rescue Medication"]}, {"label": "Sitagliptin 100 mg", "type": "ACTIVE_COMPARATOR", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks", "interventionNames": ["Drug: Matching Placebo to Ertugliflozin 5 mg", "Drug: Matching Placebo to Ertugliflozin 10 mg", "Drug: Sitagliptin 100 mg", "Drug: Metformin >= 1500 mg/day", "Biological: Insulin Glargine Rescue Medication", "Drug: Glimepiride Rescue Medication"]}], "interventions": [{"type": "DRUG", "name": "Matching Placebo to Ertugliflozin 5 mg", "description": "Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", "armGroupLabels": ["Sitagliptin 100 mg"]}, {"type": "DRUG", "name": "Matching Placebo to Ertugliflozin 10 mg", "description": "Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", "armGroupLabels": ["Ertugliflozin 5 mg", "Ertugliflozin 5 mg + sitagliptin 100 mg", "Sitagliptin 100 mg"]}, {"type": "DRUG", "name": "Matching Placebo to sitagliptin 100 mg", "description": "Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 5 mg"]}, {"type": "DRUG", "name": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 15 mg + sitagliptin 100 mg", "Ertugliflozin 5 mg", "Ertugliflozin 5 mg + sitagliptin 100 mg"], "otherNames": ["MK-8835", "PF-04971729"]}, {"type": "DRUG", "name": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 15 mg + sitagliptin 100 mg"], "otherNames": ["MK-8835", "PF-04971729"]}, {"type": "DRUG", "name": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", "armGroupLabels": ["Ertugliflozin 15 mg + sitagliptin 100 mg", "Ertugliflozin 5 mg + sitagliptin 100 mg", "Sitagliptin 100 mg"], "otherNames": ["JANUVIA\u00ae"]}, {"type": "DRUG", "name": "Metformin >= 1500 mg/day", "description": "Metformin \\>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 15 mg + sitagliptin 100 mg", "Ertugliflozin 5 mg", "Ertugliflozin 5 mg + sitagliptin 100 mg", "Sitagliptin 100 mg"], "otherNames": ["Glucophage", "Glucophage XR"]}, {"type": "BIOLOGICAL", "name": "Insulin Glargine Rescue Medication", "description": "Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 15 mg + sitagliptin 100 mg", "Ertugliflozin 5 mg", "Ertugliflozin 5 mg + sitagliptin 100 mg", "Sitagliptin 100 mg"], "otherNames": ["Lantus"]}, {"type": "DRUG", "name": "Glimepiride Rescue Medication", "description": "Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 15 mg + sitagliptin 100 mg", "Ertugliflozin 5 mg", "Ertugliflozin 5 mg + sitagliptin 100 mg", "Sitagliptin 100 mg"], "otherNames": ["AMARYL"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 26: Excluding Rescue Approach", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.", "timeFrame": "Up to 54 weeks"}, {"measure": "Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.", "timeFrame": "Up to 52 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach", "description": "This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach", "description": "Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach", "description": "A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "timeFrame": "Week 26"}, {"measure": "Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach", "description": "Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L \\* L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based \\[including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC\\] and model-based \\[beta cell function and insulin secretion rate at 9 mM glucose\\] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10\\^-9 min\\^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "timeFrame": "30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26"}, {"measure": "Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach", "description": "This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "timeFrame": "Baseline and Week 26"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes mellitus as per American Diabetes Association guidelines\n* On metformin monotherapy (\\>=1500 mg/day) for \\>=8 weeks with a Visit 1/Screening A1C \\>=7.5% and \\<=11.0% (\\>=58 mmol/mol and \\<=97 mmol/mol) OR On metformin monotherapy (\\>=1500 mg/day) for \\<8 weeks with a Visit 1/Screening A1C \\>=7.5% and \\<=11.0% (\\>=58 mmol/mol and \\<=97 mmol/mol) OR On metformin monotherapy \\<1500 mg/day with a Visit 1/Screening A1C \\>=8.0% and \\<=11.5% (\\>=64 mmol/mol and \\<=102 mmol/mol)\n* Body mass index (BMI) \\>=18.0 kg/m\\^2\n* Male or female not of reproductive potential\n* Female of reproductive potential who agrees to remain abstinent from heterosexual activity or to use 2 acceptable combinations of contraception\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus or ketoacidosis\n* History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant\n* A known hypersensitivity or intolerance to any sodium glucose co-transporter 2 (SGLT2) inhibitor or sitagliptin\n* Has been treated with any of the following agents within 12 weeks of study start or during the pre-randomization period: Insulin of any type (except for short-term use \\[i.e., \\<=7 days\\] during concomitant illness or other stress), other injectable anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), pioglitazone or rosiglitazone, other SGLT2 inhibitors, alpha glucosidase inhibitors or meglitinides, dipeptidyl-peptidase 4 inhibitor (DPP-4 inhibitor), sulfonylureas (SUs), bromocriptine (Cycloset\u2122), colesevelam (Welchol\u2122), any other antihyperglycemic agents (AHA) with the exception of the protocol-approved agents\n* Is on a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable prior to study start\n* Has undergone bariatric surgery within the past 12 months or \\>12 months and is not weight stable prior to study start\n* A history of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study start\n* Active, obstructive uropathy or indwelling urinary catheter\n* History of malignancy \\<=5 years prior to study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n* A known history of human immunodeficiency virus (HIV)\n* A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells, or a clinically important hematological disorder (e.g. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n* A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease\n* Any clinically significant malabsorption condition\n* Current treatment for hyperthyroidism\n* On thyroid replacement therapy and not on a stable dose for at least 6 weeks prior study start\n* On a previous clinical study with ertugliflozin\n* Estimated glomerular filtration rate (eGFR) (using the 4-variable Modification of Diet in Renal Disease Study Equation (MDRD) equation) \\<60 mL/min/1.73 m\\^2\n* Serum creatinine \\>= 1.3 mg/dL (115 \u00b5mol/L) for males and \\>= 1.2 mg/dL (106 \u00b5mol/L) for females\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2 times upper limit of normal\n* Hemoglobin \\<12 g/dL (120 g/L) for males and \\<11 g/dL (110 g/L) for females.\n* Participated in other studies involving investigational drug(s) 30 days prior to study start\n* Surgical procedure within 6 weeks prior to study start or major surgery planned during the trial\n* Positive urine pregnancy test\n* Pregnant or breast-feeding, or planning to conceive during the trial, including 14 days following the last dose of study medication\n* Planning to undergo hormonal therapy in preparation for egg donation during the trial, including 14 days following the last dose of study medication\n* Routinely consumes \\>2 alcoholic drinks per day or \\>14 alcoholic drinks per week or engages in binge drinking\n* Donated blood or blood products within 6 weeks of study start", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "29266675", "type": "RESULT", "citation": "Pratley RE, Eldor R, Raji A, Golm G, Huyck SB, Qiu Y, Sunga S, Johnson J, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018 May;20(5):1111-1120. doi: 10.1111/dom.13194. Epub 2018 Jan 25."}, {"pmid": "34213819", "type": "DERIVED", "citation": "Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2."}, {"pmid": "32700393", "type": "DERIVED", "citation": "Gallo S, Raji A, Calle RA, Pong A, Meyer C. The effects of ertugliflozin on beta-cell function: Pooled analysis from four phase 3 randomized controlled studies. Diabetes Obes Metab. 2020 Dec;22(12):2267-2275. doi: 10.1111/dom.14149. Epub 2020 Aug 27."}, {"pmid": "32648108", "type": "DERIVED", "citation": "Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9."}, {"pmid": "32372382", "type": "DERIVED", "citation": "Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5."}, {"pmid": "32324082", "type": "DERIVED", "citation": "Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13."}, {"pmid": "32324065", "type": "DERIVED", "citation": "Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13."}, {"pmid": "31797522", "type": "DERIVED", "citation": "Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants on \u22651500 mg/day of metformin for \u22658 weeks with A1C \u22657.5 and \u226411% at screening could directly enter a 2-week, single-blind, placebo run-in period. Participants who did not meet these criteria, received diet/exercise counseling and metformin titration (as necessary) for \\~8 weeks before entering the 2-week, placebo run-in period.", "recruitmentDetails": "The trial was conducted in 21 countries and included 242 trial centers.", "groups": [{"id": "FG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"}, {"id": "FG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks"}, {"id": "FG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "FG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "FG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "250"}, {"groupId": "FG001", "numSubjects": "248"}, {"groupId": "FG002", "numSubjects": "247"}, {"groupId": "FG003", "numSubjects": "243"}, {"groupId": "FG004", "numSubjects": "245"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "250"}, {"groupId": "FG001", "numSubjects": "248"}, {"groupId": "FG002", "numSubjects": "247"}, {"groupId": "FG003", "numSubjects": "243"}, {"groupId": "FG004", "numSubjects": "244"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "226"}, {"groupId": "FG001", "numSubjects": "217"}, {"groupId": "FG002", "numSubjects": "219"}, {"groupId": "FG003", "numSubjects": "221"}, {"groupId": "FG004", "numSubjects": "218"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "31"}, {"groupId": "FG002", "numSubjects": "28"}, {"groupId": "FG003", "numSubjects": "22"}, {"groupId": "FG004", "numSubjects": "27"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Participant moved", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "13"}, {"groupId": "FG003", "numSubjects": "9"}, {"groupId": "FG004", "numSubjects": "13"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "11"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "6"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Screen failure", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Non-compliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The Baseline Analysis Population was the All-Participants-As-Treated population. One participant randomized to the Ertugliflozin 15 mg + Sitagliptin 100 mg arm did not receive study medication.", "groups": [{"id": "BG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"}, {"id": "BG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks"}, {"id": "BG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "BG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "BG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "250"}, {"groupId": "BG001", "value": "248"}, {"groupId": "BG002", "value": "247"}, {"groupId": "BG003", "value": "243"}, {"groupId": "BG004", "value": "244"}, {"groupId": "BG005", "value": "1232"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "250"}, {"groupId": "BG001", "value": "248"}, {"groupId": "BG002", "value": "247"}, {"groupId": "BG003", "value": "243"}, {"groupId": "BG004", "value": "244"}, {"groupId": "BG005", "value": "1232"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "55.1", "spread": "10.1"}, {"groupId": "BG001", "value": "55.3", "spread": "9.5"}, {"groupId": "BG002", "value": "54.8", "spread": "10.7"}, {"groupId": "BG003", "value": "55.2", "spread": "10.4"}, {"groupId": "BG004", "value": "55.1", "spread": "9.8"}, {"groupId": "BG005", "value": "55.1", "spread": "10.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "250"}, {"groupId": "BG001", "value": "248"}, {"groupId": "BG002", "value": "247"}, {"groupId": "BG003", "value": "243"}, {"groupId": "BG004", "value": "244"}, {"groupId": "BG005", "value": "1232"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "123"}, {"groupId": "BG001", "value": "114"}, {"groupId": "BG002", "value": "93"}, {"groupId": "BG003", "value": "120"}, {"groupId": "BG004", "value": "118"}, {"groupId": "BG005", "value": "568"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "134"}, {"groupId": "BG002", "value": "154"}, {"groupId": "BG003", "value": "123"}, {"groupId": "BG004", "value": "126"}, {"groupId": "BG005", "value": "664"}]}]}]}, {"title": "Baseline Hemoglobin A1C (A1C)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%).", "populationDescription": "Participants with baseline data for A1C.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "244"}, {"groupId": "BG001", "value": "247"}, {"groupId": "BG002", "value": "242"}, {"groupId": "BG003", "value": "237"}, {"groupId": "BG004", "value": "241"}, {"groupId": "BG005", "value": "1211"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.6", "spread": "1.0"}, {"groupId": "BG001", "value": "8.6", "spread": "1.0"}, {"groupId": "BG002", "value": "8.5", "spread": "1.0"}, {"groupId": "BG003", "value": "8.6", "spread": "1.0"}, {"groupId": "BG004", "value": "8.6", "spread": "1.0"}, {"groupId": "BG005", "value": "8.6", "spread": "1.0"}]}]}]}, {"title": "Baseline Body Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "250"}, {"groupId": "BG001", "value": "248"}, {"groupId": "BG002", "value": "247"}, {"groupId": "BG003", "value": "243"}, {"groupId": "BG004", "value": "244"}, {"groupId": "BG005", "value": "1232"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "88.6", "spread": "22.2"}, {"groupId": "BG001", "value": "88.0", "spread": "20.3"}, {"groupId": "BG002", "value": "89.8", "spread": "23.4"}, {"groupId": "BG003", "value": "89.5", "spread": "20.8"}, {"groupId": "BG004", "value": "87.5", "spread": "20.5"}, {"groupId": "BG005", "value": "88.7", "spread": "21.5"}]}]}]}, {"title": "Baseline Fasting Plasma Glucose", "description": "Blood glucose was measured on a fasting basis after at least a 10-hour fast.", "populationDescription": "Participants with baseline data for Fasting Plasma Glucose.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "250"}, {"groupId": "BG001", "value": "247"}, {"groupId": "BG002", "value": "246"}, {"groupId": "BG003", "value": "240"}, {"groupId": "BG004", "value": "241"}, {"groupId": "BG005", "value": "1224"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "184.1", "spread": "52.2"}, {"groupId": "BG001", "value": "179.5", "spread": "45.7"}, {"groupId": "BG002", "value": "177.4", "spread": "46.6"}, {"groupId": "BG003", "value": "183.8", "spread": "44.3"}, {"groupId": "BG004", "value": "177.2", "spread": "49.4"}, {"groupId": "BG005", "value": "180.4", "spread": "47.8"}]}]}]}, {"title": "Static Beta-Cell Sensitivity to Glucose Index", "description": "Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L \\* L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10\\^-9 min\\^-1.", "populationDescription": "Participants with baseline data for SBCSGI.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "SBCSGI (10^-9min^-1)", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "58"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "55"}, {"groupId": "BG003", "value": "48"}, {"groupId": "BG004", "value": "50"}, {"groupId": "BG005", "value": "269"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "20.9", "spread": "26.1"}, {"groupId": "BG001", "value": "18.0", "spread": "16.3"}, {"groupId": "BG002", "value": "20.2", "spread": "21.2"}, {"groupId": "BG003", "value": "20.0", "spread": "16.6"}, {"groupId": "BG004", "value": "19.3", "spread": "21.0"}, {"groupId": "BG005", "value": "19.7", "spread": "20.5"}]}]}]}, {"title": "Sitting Systolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "250"}, {"groupId": "BG001", "value": "248"}, {"groupId": "BG002", "value": "247"}, {"groupId": "BG003", "value": "243"}, {"groupId": "BG004", "value": "244"}, {"groupId": "BG005", "value": "1232"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "129.7", "spread": "12.5"}, {"groupId": "BG001", "value": "128.9", "spread": "12.5"}, {"groupId": "BG002", "value": "128.3", "spread": "12.2"}, {"groupId": "BG003", "value": "130.2", "spread": "12.6"}, {"groupId": "BG004", "value": "129.1", "spread": "13.3"}, {"groupId": "BG005", "value": "129.3", "spread": "12.6"}]}]}]}, {"title": "Baseline estimated glomerular filtration rate, eGFR", "description": "eGFR is a parameter used to assess kidney function.", "populationDescription": "Participants with baseline data for eGFR.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "250"}, {"groupId": "BG001", "value": "248"}, {"groupId": "BG002", "value": "247"}, {"groupId": "BG003", "value": "242"}, {"groupId": "BG004", "value": "244"}, {"groupId": "BG005", "value": "1231"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "91.9", "spread": "20.6"}, {"groupId": "BG001", "value": "92.8", "spread": "21.4"}, {"groupId": "BG002", "value": "92.6", "spread": "18.2"}, {"groupId": "BG003", "value": "91.9", "spread": "20.4"}, {"groupId": "BG004", "value": "92.6", "spread": "19.2"}, {"groupId": "BG005", "value": "92.4", "spread": "20.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in A1C at Week 26: Excluding Rescue Approach", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "populationDescription": "The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the A1C change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "248"}, {"groupId": "OG002", "value": "247"}, {"groupId": "OG003", "value": "243"}, {"groupId": "OG004", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.02", "lowerLimit": "-1.14", "upperLimit": "-0.90"}, {"groupId": "OG001", "value": "-1.08", "lowerLimit": "-1.20", "upperLimit": "-0.96"}, {"groupId": "OG002", "value": "-1.05", "lowerLimit": "-1.17", "upperLimit": "-0.93"}, {"groupId": "OG003", "value": "-1.49", "lowerLimit": "-1.61", "upperLimit": "-1.36"}, {"groupId": "OG004", "value": "-1.52", "lowerLimit": "-1.64", "upperLimit": "-1.40"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "-0.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.63", "ciUpperLimit": "-0.30"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "-0.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.60", "ciUpperLimit": "-0.27"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "-0.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.61", "ciUpperLimit": "-0.27"}, {"groupIds": ["OG002", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "-0.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.63", "ciUpperLimit": "-0.30"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.", "populationDescription": "The analysis population consists of all randomized participants who received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 54 weeks", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "248"}, {"groupId": "OG002", "value": "247"}, {"groupId": "OG003", "value": "243"}, {"groupId": "OG004", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "62.0"}, {"groupId": "OG001", "value": "57.7"}, {"groupId": "OG002", "value": "57.5"}, {"groupId": "OG003", "value": "58.8"}, {"groupId": "OG004", "value": "55.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in % vs Ertugliflozin 5 mg", "paramValue": "-3.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.7", "ciUpperLimit": "5.5", "estimateComment": "Based on Miettinen \\& Nurminen method."}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in % vs. Ertugliflozin 15 mg", "paramValue": "-1.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.6", "ciUpperLimit": "6.8", "estimateComment": "Based on Miettinen \\& Nurminen method."}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in % vs. Sitagliptin 100 mg", "paramValue": "1.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.4", "ciUpperLimit": "10.1", "estimateComment": "Based on Miettinen \\& Nurminen method."}, {"groupIds": ["OG002", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in % vs. Sitagliptin 100 mg", "paramValue": "-1.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.5", "ciUpperLimit": "7.0", "estimateComment": "Based on Miettinen \\& Nurminen method."}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.", "populationDescription": "The analysis population consists of all randomized participants who received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 52 weeks", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "248"}, {"groupId": "OG002", "value": "247"}, {"groupId": "OG003", "value": "243"}, {"groupId": "OG004", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.2"}, {"groupId": "OG001", "value": "3.2"}, {"groupId": "OG002", "value": "2.8"}, {"groupId": "OG003", "value": "3.3"}, {"groupId": "OG004", "value": "3.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in % vs. Ertugliflozin 5 mg", "paramValue": "0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.3", "ciUpperLimit": "3.6", "estimateComment": "Based on Miettinen \\& Nurminen method."}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in % vs. Ertugliflozin 15 mg", "paramValue": "0.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.0", "ciUpperLimit": "4.0", "estimateComment": "Based on Miettinen \\& Nurminen method."}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in % vs. Sitagliptin 100 mg", "paramValue": "0.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.9", "ciUpperLimit": "3.9", "estimateComment": "Based on Miettinen \\& Nurminen method."}, {"groupIds": ["OG002", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in % vs. Sitagliptin 100 mg", "paramValue": "0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.5", "ciUpperLimit": "4.4", "estimateComment": "Based on Miettinen \\& Nurminen method."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach", "description": "This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "populationDescription": "The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the body weight change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Kilograms", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "248"}, {"groupId": "OG002", "value": "247"}, {"groupId": "OG003", "value": "243"}, {"groupId": "OG004", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.69", "lowerLimit": "-3.13", "upperLimit": "-2.25"}, {"groupId": "OG001", "value": "-3.74", "lowerLimit": "-4.18", "upperLimit": "-3.29"}, {"groupId": "OG002", "value": "-0.67", "lowerLimit": "-1.12", "upperLimit": "-0.22"}, {"groupId": "OG003", "value": "-2.52", "lowerLimit": "-2.97", "upperLimit": "-2.07"}, {"groupId": "OG004", "value": "-2.94", "lowerLimit": "-3.39", "upperLimit": "-2.49"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "-1.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.48", "ciUpperLimit": "-1.22"}, {"groupIds": ["OG002", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained logitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "-2.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.90", "ciUpperLimit": "-1.64"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach", "description": "Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "populationDescription": "The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the FPG change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "248"}, {"groupId": "OG002", "value": "247"}, {"groupId": "OG003", "value": "243"}, {"groupId": "OG004", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-35.73", "lowerLimit": "-40.04", "upperLimit": "-31.42"}, {"groupId": "OG001", "value": "-36.91", "lowerLimit": "-41.21", "upperLimit": "-32.62"}, {"groupId": "OG002", "value": "-25.56", "lowerLimit": "-29.93", "upperLimit": "-21.19"}, {"groupId": "OG003", "value": "-43.96", "lowerLimit": "-48.29", "upperLimit": "-39.63"}, {"groupId": "OG004", "value": "-48.70", "lowerLimit": "-53.01", "upperLimit": "-44.39"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "pValueComment": "cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "cLDA", "paramType": "Difference in the least squares means", "paramValue": "-8.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.82", "ciUpperLimit": "-2.65"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "cLDA", "paramType": "Difference in the least squares means", "paramValue": "-11.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.35", "ciUpperLimit": "-6.23"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "cLDA", "paramType": "Difference in the least squares means", "paramValue": "-18.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-24.03", "ciUpperLimit": "-12.77"}, {"groupIds": ["OG002", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "cLDA", "paramType": "Difference in the least squares means", "paramValue": "-23.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.76", "ciUpperLimit": "-17.53"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach", "description": "A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "populationDescription": "The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a post-randomization measurement for the A1C change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "248"}, {"groupId": "OG002", "value": "247"}, {"groupId": "OG003", "value": "243"}, {"groupId": "OG004", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.4"}, {"groupId": "OG001", "value": "31.9"}, {"groupId": "OG002", "value": "32.8"}, {"groupId": "OG003", "value": "52.3"}, {"groupId": "OG004", "value": "49.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "4.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.68", "ciUpperLimit": "6.40"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.68", "ciUpperLimit": "3.83"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.92", "ciUpperLimit": "4.54"}, {"groupIds": ["OG002", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.", "paramType": "Odds Ratio (OR)", "paramValue": "2.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.69", "ciUpperLimit": "3.89"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach", "description": "Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L \\* L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based \\[including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC\\] and model-based \\[beta cell function and insulin secretion rate at 9 mM glucose\\] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10\\^-9 min\\^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "populationDescription": "The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the beta-cell responsivity static component change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "SBCSGI (10^-9min^-1)", "timeFrame": "30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "67"}, {"groupId": "OG002", "value": "63"}, {"groupId": "OG003", "value": "55"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.62", "lowerLimit": "1.28", "upperLimit": "15.96"}, {"groupId": "OG001", "value": "9.71", "lowerLimit": "2.29", "upperLimit": "17.13"}, {"groupId": "OG002", "value": "21.11", "lowerLimit": "13.55", "upperLimit": "28.67"}, {"groupId": "OG003", "value": "16.24", "lowerLimit": "8.36", "upperLimit": "24.11"}, {"groupId": "OG004", "value": "11.51", "lowerLimit": "3.76", "upperLimit": "19.26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.155", "pValueComment": "cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "7.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.90", "ciUpperLimit": "18.13"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.369", "pValueComment": "cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "-4.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.54", "ciUpperLimit": "5.80"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.734", "pValueComment": "cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "1.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.66", "ciUpperLimit": "12.27"}, {"groupIds": ["OG002", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.075", "pValueComment": "cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Difference in the least squares means", "paramType": "Difference in the least squares means", "paramValue": "-9.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.17", "ciUpperLimit": "0.98"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach", "description": "This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.", "populationDescription": "The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the systolic blood pressure change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}, {"id": "OG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "250"}, {"groupId": "OG001", "value": "248"}, {"groupId": "OG002", "value": "247"}, {"groupId": "OG003", "value": "243"}, {"groupId": "OG004", "value": "245"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.89", "lowerLimit": "-5.28", "upperLimit": "-2.50"}, {"groupId": "OG001", "value": "-3.69", "lowerLimit": "-5.08", "upperLimit": "-2.30"}, {"groupId": "OG002", "value": "-0.66", "lowerLimit": "-2.07", "upperLimit": "0.76"}, {"groupId": "OG003", "value": "-3.42", "lowerLimit": "-4.82", "upperLimit": "-2.03"}, {"groupId": "OG004", "value": "-3.67", "lowerLimit": "-5.06", "upperLimit": "-2.29"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.005", "pValueComment": "cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "-2.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.69", "ciUpperLimit": "-0.83"}, {"groupIds": ["OG002", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "pValueComment": "cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "statisticalMethod": "Constrained longitudinal data analysis", "paramType": "Difference in the least squares means", "paramValue": "-3.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.94", "ciUpperLimit": "-1.09"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 54 weeks", "description": "The safety population consisted of all randomized participants who took at least one dose of trial treatment. Participants were included in the treatment group corresponding to the trial treatment they actually took. This analysis included events that occurred following the initiation of rescue therapy.", "eventGroups": [{"id": "EG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks", "seriousNumAffected": 12, "seriousNumAtRisk": 250, "otherNumAffected": 36, "otherNumAtRisk": 250}, {"id": "EG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, once daily for 52 weeks", "seriousNumAffected": 5, "seriousNumAtRisk": 248, "otherNumAffected": 43, "otherNumAtRisk": 248}, {"id": "EG002", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks", "seriousNumAffected": 8, "seriousNumAtRisk": 247, "otherNumAffected": 28, "otherNumAtRisk": 247}, {"id": "EG003", "title": "Ertugliflozin 5 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks", "seriousNumAffected": 9, "seriousNumAtRisk": 243, "otherNumAffected": 31, "otherNumAtRisk": 243}, {"id": "EG004", "title": "Ertugliflozin 15 mg + Sitagliptin 100 mg", "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks", "seriousNumAffected": 12, "seriousNumAtRisk": 244, "otherNumAffected": 38, "otherNumAtRisk": 244}], "seriousEvents": [{"term": "Blood potassium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Blood sodium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 244}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Microvascular coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Iron deficiency anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Bronchial hyperreactivity", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Duodenal ulcer haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Femoral hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Haematochezia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Small intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Obesity", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Cellulitis orbital", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Gastroenteritis norovirus", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Pneumococcal sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Pulmonary tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Nodal marginal zone B-cell lymphoma stage III", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Pancreatic neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Cholecystitis chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 244}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 244}]}], "otherEvents": [{"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 12, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 29, "numAffected": 13, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 22, "numAffected": 11, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 17, "numAffected": 9, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 42, "numAffected": 20, "numAtRisk": 244}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 14, "numAffected": 13, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 14, "numAffected": 12, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 13, "numAffected": 12, "numAtRisk": 244}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 20, "numAtRisk": 250}, {"groupId": "EG001", "numEvents": 23, "numAffected": 19, "numAtRisk": 248}, {"groupId": "EG002", "numEvents": 13, "numAffected": 13, "numAtRisk": 247}, {"groupId": "EG003", "numEvents": 18, "numAffected": 14, "numAtRisk": 243}, {"groupId": "EG004", "numEvents": 12, "numAffected": 8, "numAtRisk": 244}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina", "Bulgaria", "Canada", "Colombia", "Czech Republic", "Finland", "Hungary", "Israel", "Malaysia", "Mexico", "New Zealand", "Philippines", "Poland", "Romania", "Russian Federation", "Slovakia", "Thailand", "Ukraine", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "C000570288", "term": "Ertugliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Game", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M263808", "name": "Ertugliflozin", "asFound": "True", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}